Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose two-way crossover bioequivalence study of desloratadine 5 mg tablets under fasting conditions in healthy adults
TCTR20180202001Phase 1Not yet recruiting
- Sponsor
- Sun Pharma
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of desloratadine in allergic rhinitis (AR) and chronic idiopathic urticaria (CIU) (2 arms), sponsored by Sun Pharma. Planned start May 2018; status: not yet recruiting.
02
Drugs
desloratadine
03
Conditions
allergic rhinitis (AR)chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on TCTR20180202001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180202001.